Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTX-SPL8783
- Development stage
- Unknown
- Lead developer
- Starpharma
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
DTX-SPL8783 (also known as DEP docetaxel) is a dendrimer-drug conjugate developed by Starpharma using its proprietary DEP® (Dendrimer Enhanced Product) platform. The drug consists of docetaxel molecules covalently attached to a dendrimer nanoparticle scaffold via a controlled-release linker. This nanomedicine formulation is designed to improve the therapeutic index of docetaxel by enhancing tumor accumulation through the enhanced permeability and retention (EPR) effect, extending plasma half-life, and reducing systemic toxicities such as neutropenia and hypersensitivity reactions. DTX-SPL8783 is currently in Phase 1/2 clinical development for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), where it is being studied as both a monotherapy and in combination with other anti-cancer agents like nintedanib.
- Brand names
- DEP docetaxel
- Other names
- docetaxel–dendrimer conjugate
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on DTX-SPL8783.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTX-SPL8783.